Company news
Adhera Therapeutics Inc. (OTC:ATRX) news
Adhera Therapeutics Inc. news releases on 6ix. Latest, Jan 3, 2017: Marina Biotech Granted European Claims Covering Bacteria Mediated Gene Silencing
Press releases — page 2
Marina Biotech Granted European Claims Covering Bacteria Mediated Gene Silencing
January 3, 2017
Marina Biotech to Update Its tkRNAi Clinical Program at Biotech Showcase
December 27, 2016
Philippe P. Calais to Join Marina Biotech's Board of Directors
December 14, 2016
Marina Biotech to Present at the 9th Annual LD Micro Main Event
November 25, 2016
Marina Biotech Announces Merger with IthenaPharma
November 16, 2016
Marina Biotech Announces Resignation of Chairman, President and Chief Executive Officer J. Michael French
June 2, 2016
Marina Biotech to Acquire Late-Stage Program From Turing Pharmaceuticals
May 3, 2016
Marina Biotech Terminates Negotiations for Sale of Its Nucleic Acid Therapeutic Assets
May 3, 2016
Marina Biotech Provides 2015 Year-End Financials and Update
March 31, 2016
Marina Biotech Announces a License Agreement to Deliver a Genome Editing Technology
March 16, 2016
Microlin Bio to Acquire Nucleic Acid Therapeutic Assets of Marina Biotech
March 15, 2016
Marina Biotech Announces Evaluation and Option Agreement to Deliver a Genome Editing Technology
February 18, 2016
Marina Biotech to Explore Strategic Alternatives
February 17, 2016
Marina Biotech Reports Clinical and Preclinical Updates From SMARTICLES(R) Licensees Mirna Therapeutics and MiNA Therapeutics
November 19, 2015
Marina Biotech Receives Milestone Payment From SMARTICLES Licensee MiNA Therapeutics
November 17, 2015
Marina Biotech Announces Third Quarter 2015 Financial Results
November 16, 2015
Marina Biotech Reports That Licensee ProNAi Therapeutics Initiates 'Brighton' Phase II Trial of PNT2258 in Patients With Richter's Transformation
November 3, 2015
Marina Biotech and Hongene Biotechnology Announce License Agreement
September 28, 2015
Marina Biotech Announces Second Quarter 2015 Financial Results
August 13, 2015
Marina Biotech Announces $1.1 MM Convertible Preferred Stock Financing
August 6, 2015
Marina Biotech's CEQ508 Granted FDA Fast Track Designation for Familial Adenomatous Polyposis
August 5, 2015
Marina Biotech Expands European and Canadian Patent Protection of Its SMARTICLES Nucleic Acid Delivery Technology
June 10, 2015
Marina Biotech Announces SMARTICLES(R)-Mediated Delivery of a Double-Stranded Oligonucleotide to Immune Cells
May 5, 2015
Marina Biotech Expands Global Patent Protection of Clinical Stage Nucleic Acid Delivery Technologies
April 23, 2015
Marina Biotech Provides 2014 Year-End Financials and Update
February 25, 2015
Marina Biotech and MiNA Therapeutics Announce License Agreement for the Development of saRNA-Based Therapeutics
December 18, 2014
Marina Biotech Reports That Licensee ProNAi Therapeutics Presented Interim Phase 2 Data on Its BCL2-Targeting DNAi(R) Therapeutic at ASH 2014
December 9, 2014
Marina Biotech Reports That Partner Mirna Therapeutics Presented Interim Phase 1 Data on Its First-in-Class microRNA-34 Mimic
November 20, 2014
Rosetta Genomics and Marina Biotech Initiate First Clinical Project Under Strategic Alliance
November 18, 2014
Marina Biotech Announces Third Quarter 2014 Financial Results
November 17, 2014
OTC Markets Group Welcomes Marina Biotech to OTCQB
September 17, 2014
Marina Biotech Announces the Election of Donald A. Williams to Its Board of Directors
September 16, 2014
Marina Biotech Announces the Continued Worldwide Expansion of Its Delivery Technology Intellectual Property Estate
September 11, 2014
Marina Biotech, Inc. Announces Year-to-Date 2012 Financial Results and Highlights Corporate Accomplishments
December 6, 2012
Marina Biotech Announces that Licensee ProNAi Therapeutics Reported Phase 1 Study Results using SMARTICLES® Nucleic Acid Delivery Technology
December 5, 2012
Marina Biotech Receives Key Patent Issuance from the USPTO for its Unlocked Nucleobase Analog (UNA) Chemistry - Patent broadly covers RNA-based oligonucleotide therapeutics containing a UNA
December 4, 2012
Marina Biotech Announces Worldwide Non-Exclusive Licensing Agreement
November 29, 2012
Marina Biotech, Inc. Announces Full Year 2011 Financial Results
October 11, 2012
Marina Biotech Provides Update on Company Operations
August 22, 2012
Marina Biotech Announces Worldwide Non-Exclusive Licensing Agreement for Nucleic Acid Chemistry
August 3, 2012
Marina Biotech Ceases Most Day-to-Day Operations
June 1, 2012
Marina Biotech and Girindus Group Announce Strategic Alliance
May 21, 2012
Marina Biotech Receives Three Notices of Allowances from the USPTO and an Intent to Grant Notice from the European Patent Office
May 10, 2012
Marina Biotech Announces Worldwide Exclusive Licensing Agreement with Monsanto
May 8, 2012
Marina Biotech Regains Intellectual Property Rights to its tkRNAi™ Technology for Agriculture and Veterinary Uses
April 19, 2012
Marina Biotech Completes Dosing of Second Cohort in the Phase 1b START-FAP Clinical Trial of CEQ508
April 3, 2012
Marina Biotech, Inc. to Raise $1.2 Million in Registered Direct Offering
March 18, 2012
Marina Biotech and ProNAi Therapeutics Announce License Agreement for the Development of DNAi-based Therapeutics
March 14, 2012
Marina Biotech Presents Advances in Oral Delivery of Nucleic Acids at AsiaTIDES Conference in Tokyo
February 29, 2012
Marina Biotech Receives Notice of Allowance for U.S. Patent Related to Its Lipid Based Nucleic Acid Drug Delivery Platform
February 22, 2012